SCHEMBL17015188

SCHEMBL17015188

c1ccc(-n2ccc3c2ccc2c4ccccc4n(-c4cc5ccccc5c5ccccc45)c23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
BIRC5 O15392 1/20 0.33
PLA2G4A P47712 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
POLB P06746 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
PGR P06401 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC10 Q969S8 1/20 0.30
HDAC11 Q96DB2 1/20 0.30
HDAC8 Q9BY41 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015652 0.93 CYP1A2 (0.34) KDM4EATML3MBTL1CYP1A2CYP2C9
SCHEMBL17016136 0.91 L3MBTL1 (0.41) KDM4EATML3MBTL1CYP1A2CYP2C9
SCHEMBL17015734 0.89 CYP1A2 (0.33) KDM4EATML3MBTL1CYP1A2CYP2C9
SCHEMBL17015179 0.86 KDM4E (0.38) KDM4EATML3MBTL1CYP1A2CYP2C9
SCHEMBL17015192 0.86 KDM4E (0.40) KDM4EATML3MBTL1BIRC5PLA2G4A
SCHEMBL17015493 0.86 KDM4E (0.37) KDM4EATML3MBTL1CYP1A2CYP2C9
SCHEMBL17015339 0.85 CYP1A2 (0.40) KDM4EATML3MBTL1CYP1A2CYP2C9
SCHEMBL17015190 0.84 KDM4E (0.38) KDM4EATML3MBTL1BIRC5POLB
SCHEMBL17016135 0.84 KDM4E (0.38) KDM4EATML3MBTL1BIRC5POLB
SCHEMBL15802218 0.84 KDM4E (0.41) KDM4EATML3MBTL1BIRC5TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.